HBM Partners

HBM Partners led a $21 million Series D financing round for Gynesonics. Correlation Ventures, a new investor, took part in the financing as well as existing investors Abingworth, Advanced Technology Ventures (ATV) and InterWest Partners. Redwood City, Calif.-based Gynesonics is a women’s healthcare company that develops minimally invasive solutions for symptomatic uterine fibroids.

Gynesonics Inc., a women’s healthcare company, has raised a $21 million Series D round led by HBM Partners. New investor Correlation Ventures and existing investors Abingworth, Advanced Technology Ventures and InterWest Partners also participated. The money will be used for clinical and commercial development of the company’s treatment for uterine fibroids.

Delenex Therapeutics AG completed its Series A funding round at CHF 13.5 million ($14 million). SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners led the financing. Delenex is a Zurich-Schlieren, Switzerland-based biotechnology company that develops therapeutic antibody fragments.

Diagnostics company on the block

Numab Therapeutics AG, a clinical stage biopharmaceutical company, has raised about $110 million in Series C financing.

New York and Austria-based Hookipa Pharma, a developer of immunotherapeutics, has raised $84 million for its IPO after pricing its 6 million shares at $14 per share. The stock began trading April 18, 2019 on the NASDAQ under the ticker symbol “HOOK." BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the lead underwriters. Hookipa's pre-IPO backers included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.

Gynesonics said Jan. 3 that it raised $75 million in equity financing led by Bain Capital Life Sciences. Gynesonics existing investors, including Abingworth, Advanced Technology Ventures (ATV), Endeavour Vision, HealthCrest, InterWest Partners, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital also participated in the round. Gynesonics, of Redwood City, California, is developing treatments for uterine conditions.

iTeos Therapeutics, a Belgian biopharmaceutical company, has raised 64 million euros ($74 million) in Series B funding. MPM Capital led the round which included HBM Partners, 6 Dimensions Capital, Curative Ventures and VIVES Louvain Technology Fund.

Hookipa Biotech AG, an Austrian clinical stage biotech company, has raised $59.6 million in Series C financing. The investors included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.

Newton, Massachusetts-based Allena Pharmaceuticals, a developer of treatments for patients with rare and severe metabolic and kidney disorders, has raised about $75 million for its IPO after pricing its over 5.3 million share at $14 per share. The stock began trading November 2, 2017 on the NASDAQ under the ticker symbol "ALNA." Credit Suisse, Jefferies and Cowen are the lead underwriters. Allena's investors included Frazier Healthcare, Bessemer Venture Partners, HBM Partners, Fidelity and Partner Fund Management.

Newton, Massachusetts-based Allena Pharmaceuticals, a biopharmaceutical company focused on treating metabolic and orphan diseases, has closed $53 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Fidelity Management & Research Company, Wellington Management Company, Frazier Healthcare, HBM BioCapital and Pharmstandard International S.A.

Redwood City, California-based Gynesonics, a women's healthcare company focused on developing solutions for treating uterine fibroids, has secured $43 million in funding. Endeavour Vision and Abingworth led the round with participation from HealthCrest, InterWest Partners, Advanced Technology Ventures, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.